|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:alsoKnownAs
|
amphetamine
|
|
gptkbp:antidote
|
gptkb:naloxone
|
|
gptkbp:ATCCode
|
gptkb:N02AA09
|
|
gptkbp:broadcastOn
|
gptkb:Schedule_I_(US)
gptkb:Class_A_(UK)
|
|
gptkbp:CASNumber
|
561-27-3
|
|
gptkbp:chemicalFormula
|
C21H23NO5
|
|
gptkbp:derivedFrom
|
gptkb:morphine
|
|
gptkbp:discoveredBy
|
gptkb:C._R._Alder_Wright
|
|
gptkbp:discoveredIn
|
1874
|
|
gptkbp:firstMarketedBy
|
gptkb:Bayer
|
|
gptkbp:firstMarketedInYear
|
1898
|
|
gptkbp:hasAddictivePotential
|
true
|
|
gptkbp:hasStreet
|
gptkb:horse_race
H
brown
smack
dope
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Diamorphine
|
|
gptkbp:IUPACName
|
(5α,6α)-7,8-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diyl diacetate
|
|
gptkbp:legalStatus
|
controlled substance
|
|
gptkbp:medicalUse
|
myocardial infarction
acute pulmonary edema
severe pain
|
|
gptkbp:meltingPoint
|
173°C
|
|
gptkbp:metabolism
|
gptkb:morphine
|
|
gptkbp:molecularWeight
|
369.4 g/mol
|
|
gptkbp:origin
|
semi-synthetic
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
N (US)
|
|
gptkbp:prodrugOf
|
gptkb:morphine
|
|
gptkbp:producedBy
|
acetylation of morphine
|
|
gptkbp:PubChem_CID
|
gptkb:DB01452
5462328
|
|
gptkbp:riskFactor
|
overdose
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
addiction
nausea
constipation
respiratory depression
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
JGS12D6I9D
|
|
gptkbp:usedFor
|
pain management
palliative care
|
|
gptkbp:bfsParent
|
gptkb:Heroin
|
|
gptkbp:bfsLayer
|
6
|